Участие в клиническом исследовании может быть хорошим решением, но часто трудно найти клиническое исследование, которое подходит именно вам. В следующей таблице (на английском языке) перечислены некоторые клинические исследования для больных раком почек, которые проводятся в разных странах. В вашей стране могут проводиться другие исследования: О понимании и поиске исследований см. здесь.
Скоро. Пожалуйста, свяжитесь с Этот адрес электронной почты защищён от спам-ботов. У вас должен быть включен JavaScript для просмотра., если вам нужна информация о клинических испытаниях.
Trial name | Agents | Phase | Status | Sponsor | Further information |
ADAPTeR | Nivolumab pre and post-OP | II |
Open,
recruiting
|
Royal Marsden | click here |
Pembrolizumab-031 | Pembrolizumab (MK-3475) | I |
Open,
recruiting
|
Merck Sharp
& Dohme Corp.
|
click here |
Trial name | Agents | Phase | Status | Sponsor | Further information |
Checkmate 214 |
Nivolumab+ipilimumab
versus sunitinib
|
III | Closed to accrual | Bristol-Myers Squibb | click here |
ADAPT |
AGS-003 versus
sunitinib
|
III | Ongoing, not recruiting | Argos Therapeutics | click here |
Atezolizumab (MPDL3280 A) + bevacizumab versus
sunitinib
|
III |
Open,
recruiting
|
Hoffmann-La Roche | click here | |
Javelin Renal 101 | Avelumab + axitinib | III |
Open,
recruiting
|
Pfizer | click here |
Nivolumab vs. nivolumab+bevacizumab vs. nivolumab + ipilimumab | II |
Ongoing, not recruiting
|
MD Anderson | click here | |
Pazopanib +
interferon alpha 2a
|
I/II | Completed | Spanish Oncology Genito-Urinary Group Novartis |
click here | |
Pembrolizumab + bevacizumab |
Pembrolizumab +
bevacizumab
|
I/II |
Ongoing, not recruiting
|
Merck Sharp & Dohme Corp. | click here |
Atezolizumab +
interferon alpha 2b
|
I |
Ongoing, not
recruiting
|
Hoffman-La Roche | click here | |
Pembrolizumab + pazopanib |
Pembrolizumab +
pazopanib
|
I | Open, recruiting |
Novartis,
Merck Sharp
& Dohme Corp. |
click here |
Pembrolizumab + axitinb |
Pembrolizumab +
axitinb
|
I | Ongoing, not recruiting | Pfizer | click here |
Javelin renal 100 | Avelumab + axitinib | I |
Ongoing, not
recruiting
|
Pfizer | click here |
Trial name | Agents | Phase | Status | Sponsor | Further information |
Checkmate 025 | Nivolumab versus everolimus | III | Stopped, results published at the ECC 2015 | Bristol-Myers Squibb | click here |
Nivolumab vs. nivolumab+bevacizumab vs. nivolumab + ipilimumab | II |
Open,
recruiting
|
MD Anderson | click here | |
Pembrolizumab + interferon alpha 2b +
ipilimumab
|
I/II | Ongoing, not recruiting | Merck Sharp & Dohme Corp. | click here | |
Pazopanib +
interferon alpha 2a
|
I/II | Completed | Spanish Oncology Genito-Urinary Group Novartis |
click here | |
Pembrolizumab + bevacizumab |
Pembrolizumab +
bevacizumab
|
I/II |
Open,
recruiting
|
Merck Sharp & Dohme Corp. | click here |
Atezolizumab +
interferon alpha 2b
|
I |
Ongoing, not
recruiting
|
Hoffman-La Roche | click here | |
Cabozantinib plus nivolumab against cabozantinib + nivolumab + ipilimumab | Cabozantinib + nivolumab + ipilimumab | I |
Open,
recruiting
|
National Cancer Institute (NCI)/ Exelixis | click here |
X4P-001 in Patients With Advanced Renal Cell Carcinoma | X4P-001 + axitinib | I/II | Open, recruiting | click here | |
Pembrolizumab (MK-3475) in Combination With Epacadostat (INCB024360) | Pembrolizumab (MK-3475) + Epacadostat (INCB024360) | I/II | Open recruiting | Incyte Corporation, Merck Sharp & Dohme Corp. |
click here |
Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumours | Lenvatinib + Pembrolizumab | Ib/II | Open recruiting | Eisai Inc. | click here |
Trial name | Agents | Phase | Status | Sponsor | Further information |
Checkmate 025 | Nivolumab versus everolimus | III | Stopped, results published at the ECC 2015 | Bristol-Myers Squibb | click here |
Nivolumab vs. nivolumab+bevacizumab vs. nivolumab + ipilimumab | II |
Open,
recruiting
|
MD Anderson | click here | |
Pazopanib +
interferon alpha 2a
|
I/II | completed | Spanish Oncology Genito-Urinary Group Novartis |
click here | |
Pembrolizumab + bevacizumab |
Pembrolizumab +
bevacizumab
|
I/II |
Open,
recruiting
|
Merck Sharp & Dohme Corp. | click here |
Atezolizumab +
interferon alpha 2b
|
I | Ongoing, not recruiting | Hoffman-La Roche | click here | |
Cabozantinib plus nivolumab against cabozantinib + nivolumab + ipilimumab | Cabozantinib + nivolumab + ipilimumab | I |
Open,
recruiting
|
National Cancer Institute (NCI)/ Exelixis | click here |
X4P-001 in Patients With Advanced Renal Cell Carcinoma | X4P-001 + axitinib | I/II | Open, recruiting | click here | |
Pembrolizumab (MK-3475) in Combination With Epacadostat (INCB024360) | Pembrolizumab (MK-3475) + epacadostat (INCB024360) | I/II | Open, recruiting | Incyte Corporation, Merck Sharp & Dohme Corp. |
click here |
Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumours | Lenvatinib + Pembrolizumab | Ib/II |
Open,
recruiting
|
Eisai Inc. | click here |